Aqueous Extract of Brassica rapa Exerts Antihyperglycemic Activity in Streptozotocin-induced Diabetic Rats.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666211209114436

Ismail Bouadid, Ayoub Amssayef, Nadia Lahrach, Ahmed El-Haidani, Mohamed Eddouks

{"title":"Aqueous Extract of Brassica rapa Exerts Antihyperglycemic Activity in Streptozotocin-induced Diabetic Rats.","authors":"Ismail Bouadid, Ayoub Amssayef, Nadia Lahrach, Ahmed El-Haidani, Mohamed Eddouks","doi":"10.2174/1871529X21666211209114436","DOIUrl":null,"url":null,"abstract":"Aims: The aim of the study was to assess the antihyperglycemic effect of Brassica rapa.Background: Brassica rapa (turnip) is used as an antidiabetic plant.Objective: This work aimed to evaluate the effect of the aqueous extract of Brassica rapa seeds (AEBRS) on glycemia in vivo.Methods: The effect of AEBRS (60 mg/kg) on glycemia and lipid profiles was evaluated. Besides, preliminary phytochemical analysis and the in vitro antioxidant effect were evaluated.Results: AEBRS caused a significant reduction in blood glucose levels in diabetic rats (p<0.0001). In contrast, no significant effect was observed on lipid profiles, whereas antioxidant potential of this extract has been shown. Phytochemical analysis showed the presence of many important phytochemical families.Conclusion: The present study shows that AEBRS has a potent antihyperglycemic ability in diabetic rats.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 4","pages":"253-259"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X21666211209114436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The aim of the study was to assess the antihyperglycemic effect of Brassica rapa.

Background: Brassica rapa (turnip) is used as an antidiabetic plant.

Objective: This work aimed to evaluate the effect of the aqueous extract of Brassica rapa seeds (AEBRS) on glycemia in vivo.

Methods: The effect of AEBRS (60 mg/kg) on glycemia and lipid profiles was evaluated. Besides, preliminary phytochemical analysis and the in vitro antioxidant effect were evaluated.

Results: AEBRS caused a significant reduction in blood glucose levels in diabetic rats (p<0.0001). In contrast, no significant effect was observed on lipid profiles, whereas antioxidant potential of this extract has been shown. Phytochemical analysis showed the presence of many important phytochemical families.

Conclusion: The present study shows that AEBRS has a potent antihyperglycemic ability in diabetic rats.

查看原文本刊更多论文

油菜水提物对链脲佐菌素诱导的糖尿病大鼠的降糖作用。

目的:研究油菜的降血糖作用。背景:芜菁(Brassica rapa)被用作抗糖尿病植物。目的:研究油菜籽水提物(AEBRS)对体内血糖的影响。方法:观察AEBRS (60 mg/kg)对血糖和血脂的影响。此外，还进行了初步的植物化学分析和体外抗氧化效果评价。结果:AEBRS能显著降低糖尿病大鼠的血糖水平(结论:AEBRS对糖尿病大鼠具有明显的降糖作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.